# Atovaquone for Treatment of COVID-19

> **NCT04456153** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 60 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Experimental Group
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT04456153
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-22
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456153, "Atovaquone for Treatment of COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04456153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*